Vanguard Group Inc. Has $93.48 Million Holdings in Viridian Therapeutics, Inc. $VRDN

Vanguard Group Inc. decreased its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 3.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,331,983 shares of the company’s stock after selling 176,525 shares during the period. Vanguard Group Inc. owned approximately 5.30% of Viridian Therapeutics worth $93,484,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Farther Finance Advisors LLC raised its position in shares of Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after acquiring an additional 1,491 shares in the last quarter. Bessemer Group Inc. grew its stake in Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after purchasing an additional 1,886 shares during the period. Sei Investments Co. acquired a new stake in Viridian Therapeutics during the second quarter worth approximately $147,000. Y Intercept Hong Kong Ltd bought a new stake in Viridian Therapeutics in the second quarter worth approximately $170,000. Finally, Creative Planning acquired a new position in Viridian Therapeutics in the second quarter valued at approximately $179,000.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $28.89 on Friday. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -8.78 and a beta of 1.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.65 and a current ratio of 12.65. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $34.29. The firm’s 50-day simple moving average is $30.80 and its 200 day simple moving average is $26.72.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $15.75 million. As a group, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of the firm’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.58% of the company’s stock.

Analyst Ratings Changes

VRDN has been the subject of several recent analyst reports. Wedbush raised their price objective on shares of Viridian Therapeutics from $42.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. UBS Group initiated coverage on shares of Viridian Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. William Blair initiated coverage on shares of Viridian Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company. Needham & Company LLC reiterated a “buy” rating and set a $42.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, February 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, January 21st. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $42.43.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.